- Human pathology

Home > D. General pathology > Pathogenic agents > Therapeutics > panobinostat


Tuesday 21 February 2017


Panobinostat (trade name Farydak fayr-ah-dak) is a drug by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).

On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma, and on 28 August 2015 it was approved by the European Medicines Agency for the same use.